Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Michael Kelly | CEO, President & Director | 740.33k | -- | 1966 |
| Mr. William Joseph Radvak BASc | Co-Founder & Advisor | 60k | -- | 1963 |
| Dr. Harold Martin Punnett D.M.D. | Co-Founder & Independent Director | -- | -- | -- |
| Mr. William J. Adams C.A., CPA, CA, CPA | CFO & Corporate Secretary | 431.63k | -- | 1962 |
| Dr. Daniel D. Mikol M.D., Ph.D. | Chief Medical Officer | 793.99k | -- | -- |
| Mr. Brian McAlister | Co-Founder & Advisor | -- | -- | -- |
| Dr. Charles V. Olson D.Sc. | Senior Vice President of Technical Operations | -- | -- | 1957 |
| Ms. Elizabeth Eberhardt B.Sc. | Senior Vice President of Program Management | -- | -- | -- |
NervGen Pharma Corp.
- Sector:
- Healthcare
- Industry: Biotechnology
Description
NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. It has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.
Corporate Governance
Upcoming Events
November 14, 2024 at 1:30 PM UTC
NervGen Pharma Corp. Earnings Date
Recent Events
Recent Events Information Not Available